Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Abroad (travel likely)RecruitingPHASE2

Conditions

Primary Immune Thrombocytopenia (ITP)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Yunfei Chen) · chenyunfei@ihcams.ac.cn · +8618502220788

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Beijing, China

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE2

Greenville, United States

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

Abroad (travel likely)RecruitingPHASE2

Greenville, United States · Liverpool, Australia

Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China